The table below shows Spyre Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$169.25M
-$157.41M
-$99.91M
-$80.14M
-$53.72M
-$75.78M
Capital expenditure
-
$0.00
$0.00
$38.00K
$573.00K
$4.28M
Investing cash flow
-$143.47M
-$353.29M
-$108.39M
$57.01M
-$22.62M
-$7.60M
Dividends paid
-
-
-
-
SYRE operating cash flow (10-K history)
Spyre Therapeutics, Inc. reported operating cash flow of -$169.25M for fiscal year 2025. That is down 7.5% from -$157.41M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$18.84M (FY 2016) to -$169.25M. Figures come from the company's audited annual reports as filed with the SEC.